Loading…
← CockpitCompetitor Analysis › SMSPHARMA.NS SMS Pharmaceuticals LimitedOpen in the cockpit ↗

SMS Pharmaceuticals LimitedSMSPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 89
Mkt cap
$477M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$3.87M
20-day average traded
Fwd P/E
42.2×
forward earnings
ROIC−WACC
-4.8 pp
WACC 14.6%
Hurdle
n/a
no reverse DCF
Close · INR₹476.80
1D-2.1%
1W-8.9%
1M+9.7%
3M+32.7%
6M+16.2%
YTD+53.6%
1Y+65.6%
ATR %5.0%
Beta1.09
52w lowhigh10.9% off high

What SMS Pharmaceuticals does

Employees: 2,088

SMS Pharmaceuticals at a glance

Size SMS Pharmaceuticals (SMSPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $477M, the 861st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹476.80 on 18 Nov 2026.

Performance Over six months the shares gained 16.2%, against -9.3% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +9.4%); the operating margin is 15.6% (peer median 10.5%).

Valuation It trades at 42.2× forward earnings against a peer median of 21.3× (most expensive of 6).

Capital Return on invested capital runs 4.8 points below its cost of capital (14.6% WACC).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026SMSPHARMA.NS 112Peer median 89
Six months, rebased to 100: SMS Pharmaceuticals against the median of its 20 peers (local-currency closes).

SMS Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹9.71B₹8.83B₹7.79B₹7.06B₹5.20B
Revenue growth—+13%+10%+36%—
Gross profit₹2.00B₹1.84B₹1.53B₹1.20B₹478M
EBITDA₹1.92B₹1.68B₹1.38B₹1.15B₹535M
Net income₹1.17B₹1.02B₹691M₹498M-₹70.6M
Free cash flown/a-₹926M-₹589M-₹236M-₹282M
Capital expendituren/a₹1.31B₹1.23B₹522M₹299M
Total debt₹3.49B₹3.65B₹3.11B₹2.81B₹2.54B

Quarterly statements and history in the cockpit →

SMS Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%600624HNSAAQSTRGNX68837337053012016620003020300584002370CAPRKPL301277002107AARTIDRUGSSMSPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. SMS Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%20×40×6620003020EOLS1666AARTIDRUGSSMSPHARMA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SMS Pharmaceuticals is the large dot.

SMS Pharmaceuticals competitors and peer comparison

How SMS Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SMS Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSMSPHARMA.NSPeer medianRank in peer set
1-month return+9.7%-3.4%6th highest of 21
6-month return+16.2%-9.3%6th highest of 20
Distance from 52-week high-10.9%-38.3%5th highest of 21
Revenue growth (TTM)+13.0%+9.4%9th highest of 20
Operating margin15.6%10.5%5th highest of 19
Forward P/E42.2×21.3×most expensive of 6
ROIC minus cost of capital-4.8 pp-3.2 pp9th lowest of 18
EV / EBITDA24.8×12.1×2nd most expensive of 5
Net debt / EBITDA1.6×0.2×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%n/an/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%n/a-3.8%+0.7%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%n/an/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%24.9×24.8%+126.7%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%28.5×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%n/an/an/a
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%n/an/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%n/a44.1%+1.0%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%

Questions

Which companies are SMS Pharmaceuticals's closest peers?
The cockpit's peer set: Shanghai Fudan Forward S&T (600624.SS), Hansa Biopharma (HNSA.ST), Aquestive Therapeutics (AQST), REGENXBIO (RGNX), Shanghai MicuRx Pharmaceutical (688373.SS), YungShin Global (3705.TW), ChengDa PharmaCeuticals (301201.SZ), Handa Pharmaceuticals (6620.TWO).
Is SMS Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 42.2× against a peer median of 21.3×, most expensive of 6 in its peer set.
How has SMS Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +16.2% against -9.3% for the median peer; over one year +65.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.